Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antibiotic eye drops study

This article was originally published in The Tan Sheet

Executive Summary

"Healthy children with acute conjunctivitis do not need an ocular antibiotic at first presentation to primary care," Peter Rose, MD, Department of Primary Health Care, University of Oxford, et al., find in a study published in The Lancet. The randomized, double-blind trial compared the effects of chloramphenicol eye drops to placebo in 326 children age 6 months to 12 years. Clinical cure of eye infection occurred by day seven in 83% of children in the placebo group and 86% of those treated with the antibiotic, the authors state. Rose et al. advise forgoing medical consultation unless the child's symptoms are "unusual" or persist for more than a week. The UK's Medicines & Healthcare products Regulatory Agency approved chloramphenicol 0.5% for pharmacy sale in June (1"The Tan Sheet" June 13, 2005, In Brief)...

You may also be interested in...



Antibiotic OTC in UK

Nottingham-based Optrex is launching Optrex Infected Eyes Eye Drops, the first nonprescription antibiotic eye drop for the treatment of conjunctivitis, expected to appear on UK pharmacy shelves by the end of June. Britain's Medicines & Healthcare products Regulatory Agency approved chloramphenicol 0.5 % eye drops for the treatment of acute bacterial conjunctivitis in adults and children aged two and older for pharmacy sale June 8. MHRA says it has weighed safety and bacterial resistance risks and is "convinced that the potential health benefits outweigh any risks to patients or to the community at large." Boots Pharmacy also will offer a private-label equivalent, according to MHRA...

US FDA And NIST Form Partnership To Boost Advanced Manufacturing Techniques

The US FDA and NIST have agreed to help industry modernize and update pharmaceutical manufacturing methods and to improve supply chain resilience.

Medtronic Looks To Adaptive DBS To Advance Treatment Of Parkinson’s Disease

Medtronic is sponsoring a trial to evaluate its adaptive deep brain stimulation technology, a unique feature of the Percept PC device for treating Parkinson’s disease.

Topics

UsernamePublicRestriction

Register

LL1135495

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel